Southboro, MA, United States of America

Ekambar R Kandimalla

USPTO Granted Patents = 76 

 

 

Average Co-Inventor Count = 3.7

ph-index = 21

Forward Citations = 1,378(Granted Patents)


Inventors with similar research interests:


Location History:

  • Worcester, MA (US) (1997 - 2002)
  • Southborough, MA (US) (2013)
  • Cambridge, MA (US) (2015)
  • Southboro, MA (US) (2006 - 2016)
  • Hopkinton, MA (US) (2013 - 2018)

Company Filing History:


Years Active: 1997-2018

Loading Chart...
Loading Chart...
Loading Chart...
Areas of Expertise:
Immune Regulatory Oligonucleotide
Toll-Like Receptor Modulators
Stabilized Immune Modulatory RNA
Immunostimulatory Oligonucleotide Analogues
Synthetic Agonists of TLR9
Inhibitors of Toll-Like Receptors
Immunostimulatory Properties
Gene Expression Inhibition
Autoimmune Disease Treatments
Cancer Treatment Synergy
Modified Immunostimulatory Dinucleotides
Short Immunomodulatory Oligonucleotides
76 patents (USPTO):Explore Patents

Title: Ekambar R Kandimalla: Pioneering Immune Regulatory Oligonucleotide Innovations

Introduction:

Ekambar R Kandimalla, a prolific inventor based in Southboro, MA, US, has made significant contributions to the field of immunology with a staggering 76 patents to his name. His groundbreaking work in developing immune regulatory oligonucleotides (IROs) has opened new avenues in modulating toll-like receptor (TLR) based immune responses for various health conditions.

Latest Patents:

One of his most recent patents involves the creation of immune regulatory oligonucleotide (IRO) compounds as antagonists of TLRs. These unique sequences effectively inhibit TLR-mediated signaling triggered by TLR ligands or agonists. The applications of these IROs span across a wide range of medical fields including cancer, autoimmune disorders, inflammatory conditions, infectious diseases, and more.

Career Highlights:

Having worked at esteemed organizations like Idera Pharmaceuticals, Inc. and Hybridon, Inc., Ekambar R Kandimalla has honed his skills and expertise in developing innovative solutions in the realm of immunotherapy. His patents reflect his commitment to pushing boundaries and improving the understanding of the immune system's response to various stimuli.

Collaborations:

Throughout his career, Ekambar R Kandimalla has collaborated with notable professionals such as Sudhir Agrawal and Dong Yu. These collaborations have further enriched his research and paved the way for impactful discoveries in the field of immunological interventions.

Conclusion:

In conclusion, Ekambar R Kandimalla's groundbreaking innovations in immune regulatory oligonucleotides stand as a testament to his dedication to advancing immunotherapy. His patents not only showcase his expertise but also highlight the potential of IRO compounds in revolutionizing the treatment landscape for various diseases.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…